Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Slides:

Advertisements

Similar presentations

SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,

Advertisements

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

© The Author(s) Published by Science and Education Publishing.

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Nat. Rev. Rheumatol. doi: /nrrheum

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Figure 3 Statistical approaches for the analysis of metabolomic data

Percentage of patients achieving DAS28 (CRP) < 3

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Subhadra Evans, PhD, Mona Moieni, BSc, Rebecca Taub, BSc, Saskia K

Clinical responses over time.

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Konstantinos C. Siontis et al. JACEP 2016;2:

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Gordon R. Reeves et al. JCHF 2017;j.jchf

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

STAI: higher scores reflect more anxiety (scores 20-80).

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Performance characteristics for multivariate assay SLE panel.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

Time course of levels of serum C-reactive protein (CRP; normal < 5 mg/l) and procalcitonin (PCT; normal < 0.1 ng/ml). Time course of levels of serum C-reactive.

Multivariable model of adjusted

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Flow chart representing the number of acute infectious episodes included in the study. a Scoring positive at one of the following clinical criteria: gut.

Presentation transcript:

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3, 6, 9, and 21 months. Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3, 6, 9, and 21 months. P values reflect mixed model repeated measures analyses. DAS28-CRP4S: Disease Activity Score-28-C-reactive Protein 4; RADAI: Rheumatoid Arthritis Disease Activity Index; SF-12: Short Form-12; STAI: State Trait Anxiety Inventory. Nancy A. Shadick et al. J Rheumatol 2013;40:1831-1841 ©2013 by The Journal of Rheumatology